Community-based Case Studies of Vaccine Hesitancy and the COVID-19 Response in	1
South Africa; The VaxScenes Study	2
Charles Shey Wiysonge ^{1¶} , Nancy Coulson ^{2,3¶} , Nirvana Pillay ^{2,4¶} , Sara Cooper ¹ ,	3
Candice Groenewald ^{5,6} , Zaynab Essack ^{5,7} , Saahier Parker ⁸ , Gregory Houston ⁹ , Jane	4
Simmonds ¹⁰ , Anelisa Jaca ¹ , Muyunda Mutemwa ¹¹ , Patrick DMC Katoto ¹ and Heidi	5
van Rooyen ^{8,12} .	6
¹ Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa	7
² The Sarraounia Public Health Trust, Johannesburg, South Africa	8
³ Wits Mining Institute, University of the Witwatersrand, Johannesburg, South Africa	9
⁴ School of Public Health, University of the Witwatersrand, Johannesburg, South Africa	10
⁵ Centre for Community Based Research, Human Sciences Research Council, Durban, South	11
Africa;	12
⁶ Department of Psychology, Rhodes University, Makhanda, South Africa	13
⁷ South African Research Ethics Training Initiative, University of KwaZulu-Natal,	14
Pietermaritzburg, South Africa	15
⁸ The Impact Centre, Human Sciences Research Council, Cape Town, South Africa;	16
⁹ Developmental, Capable and Ethical State research division, Human Sciences Research	17
Council, Cape Town, South Africa;	18
¹⁰ Office of the President and CEO, South African Medical Research Council, Cape Town,	19
South Africa;	20
¹¹ Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research	21
Council, Cape Town, South Africa;	22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

¹² SAMRC-Wits Developmental Pathways for Health Research Unit, University of the	23
Witwatersrand, Johannesburg, South Africa	24
	25
* Correspondence: Charles.Wiysonge@mrc.ac.za (C.S.W.) and nirvana@sarraounia.org	26
(N.P.).	27
[¶] CS Wiysonge, N Coulson, and N Pillay contributed equally to this manuscript and share	28
joint first authorship.	29
	30
Funding: The APC is funded by the South African Medical Research Council and the study	31
is funded by the Human Sciences Research Council, South Africa.	32
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in	33
the design of the study, in the writing of the manuscript, or in the decision to publish the	34
results.	35
Data Availability Statement: Not applicable.	36

38

Abstract:

Background

South Africa has reported more than half of all COVID-19 cases and deaths in Africa. The 42 South African government has launched a large COVID-19 immunization campaign with the 43 goal of reaching more than 40 million individuals. Nonetheless, certain international, largely 44 internet-based surveys have shown a significant proportion of vaccine hesitancy in South 45 Africa. This study aims to determine and co-create with local stakeholders a comprehensive 46 understanding of vaccine hesitancy and opportunities to support the promotion of other 47 COVID-19 health-promoting behaviours at community level. 48

Methods and design

A mixed-methods, multiple case-study design; informed by the socio-ecological model of 50 behaviour change. Four socio-economically diverse communities across South Africa will be 51 selected and data collection will take place concurrently through three iterative phases. Phase 52 1 will provide insights into community experiences of COVID-19 (response) through desktop 53 mapping exercises, observations, in-depth interviews, and focus group discussions (FGDs) 54 designed as expression sessions with local stakeholders. Phase 2 will explore the extent and 55 drivers of community acceptance of COVID-19 vaccines. This phase will comprise a 56 quantitative survey based on WHO's Behavioural and Social Drivers of Vaccination tool as 57 well as further FGDs with community members. Phase 3 will involve cross-case study 58 syntheses and presentation of findings to national role-players. 59

Discussion

This study will provide ground up, locally responsive, and timeous evidence on the factors ⁶¹ influencing COVID-19 health-seeking behaviours to inform ongoing management and ⁶²

40

41

49

mitigation of COVID-19 in South Africa. It will also provide insights into the applicability of63a novel vaccine hesitancy model in Africa.64

Keywords: South Africa; COVID-19 response; vaccine hesitancy; case studies; behavioural 65 and social drivers of vaccination; non-pharmaceutical interventions 66

67

1. Introduction

68

South Africa first went into national lockdown on 26 March 2020 in response to the coronavirus 69 disease 2019 (COVID-19) pandemic and has since aligned with international guidance led by 70 the World Health Organization (WHO) on how to manage the unprecedented pandemic in the 71 face of emergent scientific evidence [1, 2]. Lockdown regulations implemented in varying 72 degrees by the South African government responded to the waves of COVID-19 amidst 73 increasing uncertainty and social and structural damage to South Africa [3]. During the first 74 quarter of 2021, the country experienced serious levels of COVID-19 infections as the second 75 wave of the COVID-19 epidemic unfolded across the country [4]. Internationally and locally, 76 new variants of COVID-19 were found to be more infectious and the surge in COVID-19 cases 77 at the beginning of 2021 was more serious than the infection levels experienced at the start of 78 the pandemic in 2020 [5]. 79

80

The scientific pursuit of biomedical interventions to manage COVID-19 saw the proliferation 81 of studies on drug and vaccine efficacy during 2020 [6]. Over the year, the need to manage and 82 translate the changing landscape of COVID-19 evidence as it emerged was ever-present. This 83 complicated the implementation and maintenance of behavioural interventions regarding non-84 pharmaceutical interventions (NPIs), but also emphasised the need for NPIs given we had 85 nothing else at the time. In early 2021, NPIs were the only available and accessible methods to 86

reduce and prevent the spread of COVID-19 in the country [1, 2]. At the same time, the safety 87 and efficacy of a number of COVID-19 vaccines had been established and the manufacture, 88 procurement, and rollout of these vaccines was a global priority [7]. Contrary to high-income 89 countries, at the beginning of 2021, limited numbers of vaccine doses had been procured for 90 South Africa and ongoing procurement and rollout was uncertain [8]. However, vaccinating 91 the South African population at scale with efficiency was a top government priority. COVID-92 19 vaccine uptake will involve behaviour change at a large scale as the government aims for a 93 vaccination coverage of at least 67% of the South African population in order to control 94 COVID-19 infections in the country [9]. 95

96

Vaccine hesitancy is one of the main challenges to be addressed for the vaccine programme to 97 work in South Africa [10]. Vaccine hesitancy, according to WHO's global working group on 98 "Measuring Behavioural and Social Drivers of Vaccination" (BeSD) is a "motivational state of 99 being conflicted about, or opposed to, getting vaccinated" which includes intentions [11]. 100 Limited evidence available in early 2021 showed wide variation in COVID-19 vaccine 101 hesitancy from 18% to 48% across various time points and geographical locations in South 102 Africa [12, 13]. Many elements could have contributed to the vaccine hesitancy. For example, 103 previous experiences that communities have of the delivery of healthcare services could 104 influence both vaccine intentions and uptake [14]. Contextual factors that shape the enabling 105 environment for vaccine uptake within a middle-income country like South Africa might be 106 expected to play a bigger role in levels of vaccine hesitancy when compared with the results 107 found in other studies which are largely conducted in high-income countries [15, 16]. For 108 example, the availability and cost of transport is regularly a barrier to access to healthcare 109 services in resource constrained communities [17, 18]. In addition, the dominance of social 110 media has been shown in a global study to directly impact on vaccine uptake [19]. Even before 111

the COVID-19 pandemic, South Africans were increasingly finding themselves in echo 112 chambers of fake information about vaccination on social media and the internet [20-26].

114

Ensuring optimal uptake of COVID-19 vaccines in South Africa would thus involve multiple 115 factors including knowledge, creating an enabling environment, addressing social influences, 116 and personal motivation [18, 27, 28]. The preceding sections highlight the need for a ground 117 up, contextually informed approach, that recognises the lived experience and understanding of 118 individuals and places them in the social world in which they live and work. That was the 119 rationale for the proposed VaxScenes Study, which aims to determine and co-create with local 120 stakeholders in four diverse South African communities, a comprehensive understanding of 121 vaccine hesitancy and opportunities to support the promotion of COVID-19 health seeking 122 behaviours. 123

124

125

2. Materials and Methods

The specific objectives are to:

- Create a community-based COVID-19 relevant geographic information system (GIS) 127
 picture that can be used for local planning in the COVID-19 response, including for 128
 vaccination and NPIs to curb the spread of COVID-19. 129
- Document stories of the lives of community members affected by COVID-19 sickness, 130 death, and economic loss in four communities.
 131
- Use the socio-ecological model to provide a community level assessment of the barriers 132
 and enabling factors at various levels (personal, interpersonal, community, and 133
 social/political) to vaccine acceptance and for ongoing adherence to behavioural measures. 134

- Pilot the BeSD survey tool to provide guidance on its application in South Africa and to 135 baseline vaccine hesitancy at the local level.
- Co-create with community-level stakeholders, context sensitive strategies to address 137
 vaccine hesitancy and COVID-19 health seeking behaviours to guide both local and 138
 national responses. 139

140

141

136

Four community-based case studies will be undertaken using the socio-ecological model [29]. The research methods to be applied in the case studies are described in further detail in 142 the following sections. Each component of data collection will be complemented by a process 143 of engagement with stakeholders at the community level, described as action research [30]. 144 These stakeholders will be identified during community-level mapping, and will include local 145 community leadership and service providers, such as health facility managers and school 146 principals. These and other key informants will be interviewed and then invited to participate 147 in workshops to contribute to the interpretation of findings and to co-create community-level 148 strategies to address vaccine hesitancy and to strengthen the COVID-19 response as findings 149 become available. 150

2.1. Conceptual framework

We propose using the socio-ecological model [29] for behaviour change as a framework to understand how to increase COVID-19 vaccine uptake by looking at barriers and enabling 153 factors at various levels, ranging from the individual to the interpersonal (the influence of 154 family, peers) to the community, and to the wider context (policy, infrastructure, resources). 155 Health messaging and correct information, although important, is often not enough for people 156 to implement sustainable behaviour change. The socio-ecological model acknowledges that for 157 any behaviour change to be maintained and sustained, it needs to happen at many different 158

151

levels. Information about the COVID-19 vaccine in isolation to other interventions will not be 159 sufficient to get the uptake required for herd immunity; information and strategies that address 160 vaccine hesitancy and that motivate people to access COVID-19 vaccines are also needed. It is 161 critical to behaviour change in a community that all four of the levels - personal, interpersonal, 162 community, and social/political - be capacitated for a change in behaviour to occur in many 163 people and then be maintained and sustained. Box 1 illustrates how the different levels of the 164 socio-ecological model can be applied to address vaccine hesitancy. In practice, we will 165 contextualise tools recently developed by the BeSD working group and use them in this study. 166 The BeSD framework consists of four domains that could potentially shape vaccine intentions 167 and uptake, namely, what people think and feel about vaccines; social processes that drive or 168 inhibit vaccination; individual motivations (or hesitancy) to seek vaccination; and practical 169 factors that shape the experience of seeking and receiving vaccination [14]. 170

Box 1: Applying the socio-ecological model to address vaccine hesitancy

<u>Individual (Self)</u>: understand the information about the vaccine (know that it is available and it is recommended that you get it), be motivated to get it, and be able to get access

Interpersonal: getting the vaccine needs support from partners, family members, and peers, or at least encouragement for this behaviour

<u>Community</u>: getting the vaccine needs to become a social norm and the socially accepted and expected thing to do. You need to be able to access the vaccine easily and safely at a local primary healthcare facility, doctor or workplace. Religious organisations, community organisations, local leaders, traditional leaders, traditional healers, and other influencers (social and political) need to be supportive of vaccine uptake

Environment: At a public policy level, the availability of the vaccine needs to be secured and the vaccine needs to be available. Resources need to be available to place vaccination centres within easy reach of the community.

The BeSD tools include qualitative tools (in form of guides for in-depth interviews with ¹⁷² stakeholders), quantitative tools (that is, questionnaires for population surveys), and a ¹⁷³ guidebook to support implementation of the tools. The tools focus on childhood vaccination ¹⁷⁴

and COVID-19 vaccination for health workers and for adults [14]. We will adapt the BeSD 175 COVID-19 vaccination tools for adults to our local context [31]. 176

Figure 1. The Behavioural and Social Drivers of Vaccination

Framework. Source: The BeSD Working Group [11, 14].

2.2. Study design

181

This research is designed as multiple case studies of four sites. Case study research is empirical 182 research that explores a contemporary phenomenon within its real-world context [32]. Case 183 studies are especially useful when the boundaries and interface between the "phenomenon" (or 184 "the case") and the "context" are not so clear. Case studies usually rely on multiple sources of 185 data. In our study, the "phenomenon" is the introduction of COVID-19 vaccination into the four 186 selected communities in South Africa with their different contextual factors, histories, and 187 experience of COVID-19. Case studies are dominated by 'how and why' research questions. By 188 adopting an approach that relies on more than one data collection method, it is possible through 189 a case study to describe, explore, and explain the "how and why" of possible vaccine hesitancy 190 without presuming at the outset to know the contextual and other factors that are shaping local 191 behaviour. The research methods will be carefully replicated at each site; the underlying goal 192 being either that the research will provide the replication of results across sites or that the case 193 studies will provide theory that can predict either similar or contrasting findings across different 194 communities [32]. In either case, multiple case studies will provide evidence that will be 195 helpful to the activities of the South African Government in addressing vaccine hesitancy. 196

2.3. Study settings

Table 1 shows the site selection of the four case studies. Convenience and purposive sampling 198 were used in the selection of sites. Convenience sampling ensured that some sites which are 199 well known to the study team with established research and community networks to facilitate 200 speedy data collection can be used. Purposive sampling will allow the team to include a mix of 201 sites from different South African provinces badly affected by COVID-19 and to include 202 communities that reflect formal and informal urban contexts as well as peri-urban and rural 203 environments. Study sites were selected in KwaZulu Natal, Gauteng, and Western Cape 204 provinces, which were the three provinces with highest numbers of COVID-19 cases in South 205 Africa in early 2021 [33]. In KwaZulu Natal Province we selected an urban community 206 (Wentworth) and a semi-rural one (Sweetwaters). In Gauteng Province we selected an urban 207 informal community known as Alexandra. Finally, in the Western Cape Province, an urban 208 middle-class community was selected. The selected sites have markedly different populations 209 as shown in Table 1. 210

					Provincial
Site	Province	Administrative description	Туре	Population	COVID-19
					data*
A 1 1	Contains	Ward 76, RegionE City of	Urban,	798,014	386,770 cases;
Alexandra	Gauteng	Johannesburg	informal		10,195 deaths
Dedanda	Western Cone		111	22 100	268,507 cases;
Rylands	western Cape	Ward 46, Athlone, City of Cape Town	Urban	32,199	10,195 deaths
<u> </u>	KwaZulu-	Vulundlela, Umgungundlovu District	Q		
Sweetwaters	Natal	Municipality	Semi-rural	35,000	
					311,877 cases;
Wentworth	KwaZulu-	Ward 66,	Urbon	145.040	9 112 deaths
	Natal	eThekwini Municipality	Urban	145,949	8,443 deaths

Table 1. Characteristics of the four case study sites.

The source of the provincial COVID-19 data is the South African National213Department of Health, as reported on 29 January 2021 [33].214

2.4. Study phases

At each case study site, teams will use a mixed methods approach to data collection with 216 quantitative and qualitative elements to address all research objectives. Figure 1 illustrates the 217 overall approach to the study that is to be replicated in each of the case study sites. At each 218 site data collection and the dissemination of findings will be organised into three distinctive 219 phases. 220

222

215

Figure 2. The three phases of data collection and dissemination for the VaxScenes Study. (BeSD, behavioural and social drivers of vaccination; KIIs, key informant interviews; FGDs, focus group discussions; GIS, geographic information system; MAC, ministerial advisory committees)

Phase 1 will provide a preliminary snapshot of the community experiences of COVID-19 and 228 the responses to it. This will be achieved using GIS maps to visualise the spatial arrangements 229 for infrastructure, housing, employment, and public and private services, as well as population 230 centres and COVID-19 statistics. Thereafter key informant interviews (KIIs) with community 231 stakeholders and focus group discussions (FGDs) designed as expression sessions will provide 232 a narrative about the COVID-19 experience in the local community. The local map and 233 narrative will be shared with key informants at a workshop where the findings will provide the 234 basis for the selection of population groups for a deeper investigation of vaccine hesitancy in 235 phase 2. 236

237

In **Phase 2**, the case study research design will throw a spotlight on community acceptance of 238 COVID-19 vaccines. A quantitative survey and further FGDs will be conducted with groups in 239 the community. The findings of the survey and focus group discussions will be shared with the 240 key informants at a second workshop and this will form the basis for stakeholders co-creating 241 strategies to maximise vaccine acceptance within their ward. 242

243

Phase 3 will involve cross case study syntheses as appropriate, and the presentation of findings 244 to national role-players including the National Department of Health (NDoH), the Ministerial 245 Advisory Committee (MAC) on COVID-19 Vaccines, the MAC on COVID-19, and the 246 Behaviour Change Communication MAC. In Phase 3 researchers will prepare an integrated 247 report across all four case study sites. Academic papers will be prepared and complemented by 248 a comprehensive literature review of vaccine hesitancy and behavioural interventions as 249 specifically experienced in Africa and in other cases where local perspectives about vaccine 250 acceptability are integrated into national vaccine programmes. 251

2.5. Study population

Table 2 summarises the study population for both the qualitative and quantitative components.	254
The study will only recruit people who are aged 18 years or older.	255

Table 2. Sampling method and size per research methodology type at four case sites.

257

256

Research	Sampling	Sample size per site	Sample size for all 4
methodology	method		sites
Phase 1 research			
activities			
Key informant	Purposive and	15-20 KIIs with	70-80 KIIs with
interviews(KIIs)	snowballing	stakeholders	stakeholders
Observation	Observation sites	Visits to 6 meeting	Visits to 24 meeting
	selected through	spaces in the	spaces in the
	mapping & KIIs	community for	community for
		observation	observation
Focus group	Purposive	3 expression sessions	12 expression sessions
discussions (FGDs) -		each with 6	with a total of 72
expression sessions		participants who have	participants who have
		been badly affected by	been badly affected by
		COVID-19 either	COVID-19 either
		through sickness,	through sickness,
		death, or economic	death, or economic
		loss.	loss.
Phase 2 research			

activities				
BeSD survey	Convenience	300 respondents from	1200 respondents	
	sampling	a maximum of 3	from priority target	
		priority target groups	groups forvaccination	
		for vaccination		
FGDs with semi-	Purposive	3 FDGs with between	12 FGDs with	
structured guides		6 to	between 72 and 96	
		8 participants with	individuals with	
		stakeholders who	stakeholders who	
		shapesocial norms	shape social norms	

258

259

260

2.5.1. Study population for qualitative component

During Phase 1 we will conduct 15-20 key informant interviews (KIIs) with stakeholders who are purposively selected. The proposed list of ward-based key informants includes but is 261 not limited to local political and traditional leadership, clinic and health service leaders, school 262 principals, faith-based leaders, business leaders, government officials, local taxi associations, 263 local civic leaders, local trade union leadership, and private healthcare practitioners. It is 264 expected that key informants at each site will include many of the individuals listed above, but 265 also that at each site a unique list of key informants will emerge iteratively. During the 266 interviewing of key stakeholders, researchers will enquire after the names of other potential 267 key informants to ensure that influential leadership at the local level is not inadvertently 268 overlooked during the mapping exercise. Snowball sampling would ensure that the research 269 team identifies all significant individuals shaping the local COVID-19 response who may, for 270 example, be outside of the immediate community such as provincial and/or national role-271 players. 272

Participants for both types of FGDs will be purposively identified. Three FGDs of each type will be held at each site. During Phase 1 no more than six participants will be recruited into the 274 expression sessions. The sessions will be implemented in a group setting consisting of no more 275 than six participants. The small sample size here is deliberate, to allow for meaningful 276 engagement in the focus group discussions. Participants who have been badly affected by 277 COVID-19 either through sickness, death, or economic loss will be recruited into the 278 expression sessions. A social worker will be available at each site to ensure that any trauma 279 experienced during or after the sessions can be appropriately referred. In Phase 2, between six 280 and eight participants will be purposively recruited into the FGDs that are to be supported with 281 a semi-structured interview guide. Specifically, this group of respondents are those best placed 282 to influence social norms around vaccination in the community. The participants for these 283 FGDs will be identified at the end of Phase 1 and in discussion with community stakeholders. 284 This could include healthcare workers, faith-based leaders, community leadership, and other 285 community and social workers. 286

2.5.2. Study population for the quantitative component

The selection of survey respondents will be guided by priority populations in line with the rollout phases and target groups for COVID-19 vaccination as determined by the NDoH. The 289 findings of Phase 1 research and consultation with local stakeholders will also determine the 290 final selection of the survey respondents. It is expected that it may include priority groups at 291 risk of COVID-19 (the elderly), essential service workers identified in each study site (for 292 example, teachers, taxi drivers, and people working in institutional care facilities) and other 293 adult men and women in the selected communities. The participants should also be resident or 294 working in the community where the survey is to be conducted. The study will use non-295 probability convenience sampling because it is a cost- and time- effective method. It is 296 proposed to collect 300 completed survey questionnaires at each site. Non-probability 297

288

287

sampling can account for smaller samples such as 300 per site. A sample comprising at least 298 300 participants per site allows for the detection of small correlations (r=0.2) with at least 95% 299 power [34].

2.6. Data collection

Three discrete but interlinking components of data collection will be undertaken for each case study site. These are: desk review of demographic and epidemiological profiles and available GIS mapping and literature; qualitative data collection methods; and quantitative data collection using a questionnaire.

2.6.1. Desk based methods

A desktop mapping exercise using existing GIS and COVID-19 related document collection will complement qualitative and quantitative data collection at each site. The desk review will 308 aim to create a comprehensive picture of each community. This will include a demographic 309 and epidemiological profile, and mapping of the local community using general spatial 310 planning data commonly stored on GIS and the collection of documents that describe the 311 COVID-19 response in the community. A COVID-19 relevant picture of each community will 312 be created, using GIS to support this, and will include: COVID-19 epidemiological profile, 313 population (numbers, priority and at-risk groups, and population centres), services and local 314 infrastructure (schools, clinics, transport routes) taxis, buses, private, civil society (faith-based, 315 women's groups, non-governmental organisations, government offices), relevant government 316 departments, police, private sector (large employers and trade union representatives, private 317 health care, COVID-19 response (who has done what where and the size of the spend). The 318 desk-based mapping and evidence review will inform the sampling for the key informant 319 interviews with stakeholders described later. 320

2.6.2. Qualitative methods

321

307

306

301

2.6.2.1. Key informant interviews

The mapping exercise will identify key stakeholders in each community to be approached for interview. Researchers will use a semi-structured interview guide (see Appendix A1), 324 adapted from the BeSD qualitative tools for COVID-19 vaccination, for KIIs. The latter will 325 be conducted face-to-face at the community level or over virtual platforms; depending on 326 COVID-19 conditions at the time, participant preferences, and other practical considerations. 327 The KIIs will explore a range of themes including: participants' personal, family and community 328 experiences of COVID-19; the impact of COVID-19 on personal and work life; experience of 329 varying lockdown regulations; experience of adherence to NPIs; understanding of COVID-19 330 vaccines; how COVID-19 has shaped their leadership role in the community; and expectations 331 for the future. All research teams will consist of a mix of local language and English-speaking 332 researchers. With permission of participants, interviews will be audio-recorded and thereafter 333 translated as necessary and transcribed. 334

2.6.2.2. Observation

On-site researchers will conduct observations of community life in the case study sites. These observations will be centred around locations where community members meet, such as 337 shopping centres, street trading spaces, and/or taxi ranks. The purpose of the observations will 338 be to better understand local community life as well as to document observation about NPI 339 adherence as well as COVID-19 related media and facilities; such as for hand washing. 340

2.6.2.3. Focus group discussions

Two types of FGDs will be conducted. The first type will apply an approach called "expression sessions" [35]. The second type of FDG will rely on a semi-structured FGD guides. 343 Expression sessions will be conducted in Phase 1 of the research activities. The second type of 344 FGD will follow in Phase 2. All FGDs will be conducted face-to-face at the research site and 345 will follow COVID-19 precautions including physical distancing, the wearing of face masks, 346

322

335

336

and a well-ventilated venue. FGDs will be capped at six participants for expression sessions and 347 eight for other FGDs. The tools will be piloted in one community and amendments made 348 thereafter. All FGDs will be audio recorded with the permission of participants. Thereafter 349 recordings will be translated as necessary and transcribed. 350

2.6.2.3.1. Expression session focus group discussions

Expression sessions will be facilitated with participants in the community who have been severely affected by COVID-19 through personal ill-health, family loss, and/or economic 353 adversity. An expression session is a newly developed approach to collect verbal, visual, and 354 audio-visual data from participants [36]. This approach is informed by the photovoice 355 methodology where participants are required to take photos in response to research questions 356 [37]. The approach encourages active participation in research, and meaningful reflection 357 and engagement with research questions, which is important in the context of COVID-19 358 and vaccine hesitancy. Expression sessions encourage participants to respond to probes by 359 sharing 'something' rather than photos only. 'Something' could be images, photos, videos 360 (self-taken, downloaded online, or from a book or magazine), a song (audio or lyrics), a drawing 361 (self-drawn or a picture of a drawing), or a poem (self-written or not). Participants will be 362 encouraged to bring their 'somethings' to a FGD. Participants will receive a brief formative 363 training session on the methodology along with a set of two research probes to which they can 364 respond by bringing 'something' (see Appendix A2). Following the formative session, 365 participants will have one week to gather their 'somethings'. Expression session FGDs will be 366 facilitated by two researchers and will be conducted in the dominant or preferred language of 367 the group. Each team will include a researcher with local language capacity. Participant 368 information sheets and consent forms will be translated into the local language. 369

2.6.2.3.2. Focus group discussions with semi-structured guides

370

351

Conventional FGDs will be conducted with three stakeholder groups who are able to address vaccine hesitancy in the community and provide support to the local response to improve acceptance and uptake of vaccines. These FDGs will focus on how to strengthen the community response to vaccine hesitancy and to promote on-going COVID health seeking behaviours. A semi-structured FGD protocol is found in Appendix A3. FGDs will be facilitated by two researchers. It is anticipated that most of these FGDs can be conducted in English but researchers with local language capacity will be included in each research team. Participant information sheets and consent forms will be translated into the local language.

2.6.3. Quantitative methods

For the quantitative component of the study, we adapted the BeSD quantitative COVID-19 vaccination tool for adults [14]. The tool consists of a questionnaire that assesses four 381 domains i.e., what adults think and feel about COVID-19 vaccines; social processes that drive 382 or inhibit COVID-19 vaccination; individual motivations (or hesitancy) to seek COVID-19 383 vaccination; and practical factors that shape the experience of seeking and receiving COVID-384 19 vaccination [14]. The BeSD quantitative tool adapted for this study is provided in Appendix 385 A4. The survey will be conducted in English, Afrikaans, and isiZulu since these are 386 predominant languages spoken in the selected communities. Participant information sheets and 387 consent forms will also be translated into the local language. The survey tool will be piloted 388 among 100 adults in one of the first community sites. Where needed additions will be made to 389 the survey to assist with the translation of specific terms. Data will be captured onto tablets 390 during face-to-face interviews conducted by well-trained researchers working in each 391 community site. The researchers will wear masks, practice physical distancing when 392 approaching potential participants, use hand sanitisers regularly, and adhere to all other 393 COVID-19 protocols. Should the period for interviews in any given community coincide with 394 the period of lockdown, face-to-face interviews will be replaced with online questionnaires. 395

380

379

2.6.4. COVID-19 precautions

The research team will adopt an approach to data collection that is compliant with all the rules pertaining to the COVID-19 response. It is expected that some qualitative data collection ³⁹⁸ will be virtual and meetings to discuss findings with local stakeholders may be virtual where ³⁹⁹ appropriate. Onsite researchers will use personal protective equipment (including face masks ⁴⁰⁰ and hand sanitisers) and with provide PPE to FGD participants. Meetings and FGDs will be ⁴⁰¹ made in well ventilated venues and seating will be appropriately physically distanced. ⁴⁰²

2.7. Data analyses

Iterative analyses of all data will occur at each community site as the research team moves from Phase 1 to Phase 3. Data will be triangulated across methods to promote validity. Casespecific and cross-case syntheses will be undertaken as appropriate and as determined by the findings. 407

2.7.1. Qualitative data analyses

Qualitative data will be audio recorded, transcribed, and translated where required. Transcripts will be organised and stored using qualitative data software such as MaxQDA and 410 ATLAS.ti (version 9) to facilitate coding and analyses of data. Qualitative data will be subject 411 to thematic analysis [38]. A code book will be developed for the data including both inductive 412 and deductive codes [39], but emphasis will be placed on allowing the data to determine codes 413 [40]. The codes will be discussed between the four qualitative researchers involved in the case 414 studies and with the four study principal investigators. An inter-coder agreement will be 415 established with a portion of the data to verify and enhance data credibility. 416

2.7.2. Quantitative data analyses

Quantitative data will be cleaned and stored in the Statistical Package for Social Sciences software, version 27.0 (IBM SPSS Inc, Chicago, IL). Thereafter both the SPSS version 27.0 419

409

408

417

418

396

403

404

and R/Rstudio v3 softwares will be used for data analyses. The survey data will be summarised 420 as counts and percentages for categorical variables and means with their standard deviations for 421 continuous variables. Analysis of the variance (ANOVA), chi-square tests, and equivalents will 422 be used as appropriate for group comparisons. Logistic regression models will also be used to 423 evaluate the association between selected characteristics and vaccine hesitancy as well as 424 adherence to NPIs. A basic model will be adjusted for age and sex. Expanded multivariable 425 models for the outcome "vaccine hesitancy" will be further adjusted for significant predictors 426 in basic models. Additional data analyses will include subgroup analyses conducted using 427 variables such as race, sex, socio-economic status, geographical location, education levels, and 428 occupation to match areas specific needs. A P-value less than 0.05 will be used to indicate 429 statistically significant results. 430

2.8. Ethics

This study proposal was approved by the Human Research Ethics Committees of the University of the Witwatersrand in Johannesburg, South Africa (reference: H21/02/05) on 25 March 2021; the Human Sciences Research Council of South Africa (reference: REC 12/04/21) on 20 April 2021; and the South African Medical Research Council (reference: EC022-5/2021) on 27 May 2021.

Every effort will be made to ensure that the research process is socially sensitive and respects the rights of all participants. Information sheets will be provided to all potential participants (as hard or electronical copies as the case may be) as well as verbal briefing on the nature and purpose of the interviews or FGDs, emphasising the right of individuals to refuse or withdraw from the interview or FGD at any point. A consent form for participation and for 441 audio-recording will be provided. All participation is voluntary. Participants at face-to-face 442 FGDs will be provided with refreshments.

432

437

Personal identifiers during KIIs and FGDs will not be used in the reporting and all data will be reported in a summarised form (sex, age) without attributing comments or information 445 to individuals. FGD participants will be informed that while all steps will be taken towards 446 maintaining confidentiality and anonymity, this cannot be guaranteed due to the nature of 447 sharing encouraged by FGDs. While FGD participants will know each other's identity and the 448 information shared, an environment of private sharing will be encouraged; highlighting the 449 importance of maintaining confidentiality for all participants. Furthermore, a local social 450 worker will be available at each site to support or refer any participant that experiences any 451 psychosocial concerns during or after the expression session FGDs. All data will only be used 452 for research purposes and kept with utmost confidentiality, and they will not be accessed by 453 anyone else but the research team. 454

Respondents will be reimbursed for their participation in the study. This is ethically sound and is aligned to the "time, inconvenience, and expenses" (TIE) model [41] and is endorsed by the National Health Research Ethics Council of South Africa [42]. The reimbursement amounts proposed for the study are aligned to TIE that reimburses participants for their time at a rate on par with unskilled labour rates, for their inconvenience and for any expenses (e.g., transport, childcare). The reimbursement for KIIs and FGDs is 150 South African Rands (ZAR) and for the survey is ZAR 100.

2.9. Study team

The study team is multidisciplinary, consisting of specialists in public health, epidemiology, social science, vaccinology, psychology, political science, project management, and health promotion. The team is led by four principal investigators from the three South African institutions, namely, the Human Sciences Research Council (H.v.R), the Sarraounia Public Health Trust (N.C. and N.P.), and the South African Medical Research Council (C.S.W.).

455

462

463

3. Discussion

Previous studies have shown high levels of vaccine hesitancy in South Africa [9, 13, 43]. These high levels of are most likely to be driven by multiple factors including personal, 471 interpersonal, community, and social. We therefore propose in this study to determine and cocreate with community stakeholders a comprehensive understanding of vaccine hesitancy and 473 opportunities to support the promotion of COVID-19 health seeking behaviours in South 474 Africa. The conceptual framework for the study is based on the socio-ecological model of 475 behaviour change [29] and the BeSD framework for COVID-19 vaccination [14].

Existing vaccine hesitancy measurement tools were mostly designed for use in and validated in high-income countries [10, 15]. Given that vaccine hesitancy is context specific, 478 there is a need to adapt and validate existing COVID-19 vaccine hesitancy tools for use at 479 national and community levels in South Africa. The BeSD tools, which were recently 480 developed under the auspices of WHO, measure both behavioural and social drivers of 481 vaccination. At the time this study was conceived in early 2021, the BeSD model of vaccine 482 hesitancy had not been validated in an African setting. The proposed study will therefore 483 provide insights into the applicability of a novel vaccine hesitancy model in Africa. 484

The backdrop to the proposed community-based case studies is that the benefits of models of behaviour change that are focused purely on knowledge deficit are limited. Understanding 486 both the behavioural (individual) and social drivers of vaccine hesitancy is critical to increasing 487 COVID-19 vaccine uptake in South Africa. The study applies the socio-ecological model to 488 the investigation of vaccine hesitancy. This model considers the complex interplay between 489 individual, relationship (interpersonal), community, and social factors. It allows us to explore 490 the range of factors that render people conflicted about or opposed to COVID-19 vaccination. 491 Although all levels of the socio-ecological model are relevant for communities, researchers and 492 practitioners in health promotion are often poor at articulating the integration of these levels 493

469

470

477

and how this determines effective health promotion strategies. One of the most effective 494 applications of the socio-ecological model is at the community level. This is because the 495 enablers or barriers to behaviour change in the four levels (i.e., personal, interpersonal, 496 community, social) of the model can be readily identified. For example, if a local faith leader is 497 speaking out against vaccination, it will most likely have an impact on the social norms of the 498 local community. Similarly, if the local clinic has a reputation for providing poor services, then 499 this too will affect vaccine uptake because it is a barrier to establishing an enabling environment. 500 A bottom-up approach to understanding vaccine hesitancy provides the best opportunity to 501 understand those factors that encourage or impede vaccine uptake. This is enhanced when 502 community stakeholders are actively engaged in providing an interpretation of the intersection 503 of the range of factors at the community level. 504

This mixed methods study is designed as an action research study that is responsive to the local context and is conducted to influence the ongoing management and mitigation of COVID-506 19 in South Africa. To address the issue of COVID-19 vaccine uptake, an integrated analysis 507 is necessary to provide community stakeholders with a comprehensive understanding of the 508 factors that will assist the identification of helpful health promotion activities at the local level 509 to support COVID-19 vaccine rollout. Convenience sampling is best suited for this type of 510 study, although this would limit the generalisability of the findings to all communities in South 511 Africa. However, we believe that the study will make a substantial contribution to knowledge 512 on COVID-19 response in South Africa, as the case study research will be conducted in four 513 commonplace settings in the country. 514

4. Conclusions

The COVID-19 pandemic continues to have significant health, human, social, and economic impacts on South African society. COVID-19 vaccines and non-pharmaceutical ⁵¹⁷ interventions (NPIs) currently offer the most promising means to manage the pandemic. ⁵¹⁸

505

515

However, their success depends on high levels of uptake and adherence. The aim of this study 519 is to determine and co-create with local stakeholders a comprehensive understanding of vaccine 520 hesitancy and opportunities to support the promotion of other COVID-19 health-promoting 521 behaviours. The study will utilise a mixed-methods, multiple case study design, informed by 522 the socio-ecological model of behaviour change. The study will provide ground-up, locally 523 responsive, and timeous evidence on the factors influencing COVID-19 vaccine acceptance 524 and other health-seeking behaviours to inform the management and mitigation of the pandemic 525 in South Africa. It will also provide insights into the applicability of various global vaccine 526 hesitancy models and research tools to a middle-income country in Africa. 527

Author Contributions: Conceptualization, C.S.W., N.C., N.P., H.v.R; methodology,	528
C.S.W., N.C., N.P., S.C., C.G., PDK, Z.E., S.P., H.v.R; writing-original draft preparation,	529
C.S.W., N.C., N.P., H.v.R.; writing-review and editing, S.C., C.G., Z.E., S.P., G.H., J.S.,	530
A.J. and PDK; project administration, N.C., N.P., C.G., Z.E., G.H., J.S; and funding	531
acquisition, H.v.R. All authors have read and agreed to the published version of the	532
manuscript.	533

 Informed Consent Statement: Each participant will provide written or digital informed
 534

 consent.
 535

Acknowledgments: This study is conducted by The VaxScenes Study Team which includes536Heidi van Rooyen (Human Sciences Research Council (HSRC)), Charles Shey Wiysonge537(South African Medical Research Council (SAMRC)) Nancy Coulson (Sarraounia Public538Health Trust), Nirvana Pillay (Sarraounia Public Health Trust), Saahier Parker (HSRC),539Gregory Houston (HSRC), Marilyn Couch (HSRC), Candice Groenewald (HSRC), Zaynab540Essack (HSRC), Londiwe Deborah Shandu (HSRC), Nonkululeko Khuzwayo (HSRC),541Nobukhosi Ncube (Sarraounia Public Health Trust), Jane Simmonds (SAMRC), Sara Cooper542

It is made available under a	CC-BY 4	4.0 International	license.
it is made available under a	00 01 -	T.O International	1001130.

 WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. <u>https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccination-demand-planning-2021.1</u> (accessed 22 December 2021). 2021. Cooper, S., et al., Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S. and C.S. Wiysonge, Understanding COVID-19 vaccine hesitancy. Nat Med, 2021. 27(8): p. 1338-1339. Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wilson, S.L. and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge.pdf (accessed 22 December 2021). 2018. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. Oduwole, E.O., et al., A profile of anti-vaccination lobbying on the South Africa internet, 2011-2013. S Afr 	(SA	MRC), Anelisa Jaca (SAMRC), Phelele Bhengu (University of Cape Town), Edison	543	
 Abdool Karim, S.S., <i>The South African Response to the Pandemic</i>. N Engl J Med, 2020. 382(24): p. e95. Wiysonge, C.S., <i>South Africa's War on COVID-19. Think Global Itealth.</i> 20 <i>April 2020.</i> NDOH-a. <i>National Department of Health, South Africa. Regulations and Relief.</i> 2021 [cited 2022 14 January 2021; Available from: https://sacoronavirus.co.za/evol/19-L94. NDOH-b. <i>National Department of Health, South Africa. Covid-19 Daily Updates & Cases.</i> 2021 [cited 2022 14 January 2021; Available from: https://sacoronavirus.co.za/evol/19-L94. NDOH-b. <i>National Department of Health, South Africa. Covid-19 Daily Updates & Cases.</i> 2021 [cited 2022 14 January 2021; Available from: https://sacoronavirus.co.za/evol/19-L94. Nbott-on, I., et al., <i>The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic.</i> Ann Intern Med. 2020. 34(19): p. 1866-1868. Boutron, I., et al., <i>The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pancemic candidate among frontime healthcare workers in South Africa.</i> 1972 [arccine. NbOH-e. <i>National Department of Health, South Africa.</i> Arccine updates. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/vaccine-updates. NbOH-e. <i>National Department of Health, South Africa. COVID-19: could lessons from the past help in drivining the future?</i> Hum Vaccin Immunohter, 2021: p. 1-3. NbOH-e. <i>National Department of Health, South Africa. COVID-19: vaccine hesitancy in South Africa:</i> 567 NbOH-e. <i>National Department of Health, South Africa. COVID-19: vaccine hesitancy in South Africa:</i> 578 NbOH-e. <i>National Department of Health, South Africa.</i> COVID-19: vaccine hesitancy in South Africa: 579 NbOH-e. <i>National Department of Health, South Africa.</i> 1091/2020; [available from: https://sacoronavirus.co.za/2021 [available from: https://sacoronavirus.co.za/2021 [available from: https://	Ma	vundza (SAMRC), Patrick Katoto (SAMRC).	544	
 Wiysonge, C.S., South Africa's War on COVID-19 Think Global Health. 20 Apprl 2020. 547 <i>Hugs:/News thinkgloballealth.org:article/south-africa:swarc-coid/19 (accessed 22 December 2021)</i>, 2020. NDOH-a. National Department of Health, South Africa. Regulations and Relief. 2021 [cited 2022 14 Innuary 2022], Available from: <u>https://sacoronavirus.co.za/guidelines-and-relief</u>. NDOH-b. National Department of Health, South Africa. Covid-19 Daily Updates & Cases. 2021 [cited 2022 14 January 2022], Available from: <u>https://sacoronavirus.co.za/covid-19-daily-cases!</u>. Abdool Karim, S.S. and T. de Oliveira, New SARS-Cori-2 Variants - Clinical, Public Health, and Vaccine <i>Implications</i>. N Engl J Med, 2021. 384(19): p. 1866-1868. Boutron, L., et al., <i>The COVID-N4P voccines</i>. Curr Opin Immunol, 2021. 17: p. 111-116. Sisonke. Sisonke study: a pragmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccine candidate among frontline health.core workers in South Africa. Intp://sison/hestudy.samer.ca.zd (accessed 19 September 2021). 2021. NDOH-e. National Department of Health, South Africa. Vaccine updates. 2021 [cited 2022 14 January 2022]. Tri p. 34-45. Wiysonge, C.S., et al., <i>A critical review of measures of childhood vaccine confidence</i>. Curr Opin Immunol, 2021. Tri p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: Summary of existing studies. 2021 [cited 2022] 14 January 2022]; Available from: thys:/sacoronavirus.co.ca/wicein-hesitancy-in.south.africa: south Africa: South Africa: Hum Vaccin Immunother, 2021 and the achievements of vaccina hesitancy in South Africa: South Africa: Hum Vaccin Immunother, 2021. 20(1). Cooper, S., H. van Rooyen, and C.S. Wiysonge, COVID-19 vaccine hesitancy in South Africa: 567	Ref	erences	545	
 Wiysonge, C.S., South Africa's War on COVID-19 Think Global Health. 20 Apprl 2020. 547 <i>Hugs:/News thinkgloballealth.org:article/south-africa:swarc-coid/19 (accessed 22 December 2021)</i>, 2020. NDOH-a. National Department of Health, South Africa. Regulations and Relief. 2021 [cited 2022 14 Innuary 2022], Available from: <u>https://sacoronavirus.co.za/guidelines-and-relief</u>. NDOH-b. National Department of Health, South Africa. Covid-19 Daily Updates & Cases. 2021 [cited 2022 14 January 2022], Available from: <u>https://sacoronavirus.co.za/covid-19-daily-cases!</u>. Abdool Karim, S.S. and T. de Oliveira, New SARS-Cori-2 Variants - Clinical, Public Health, and Vaccine <i>Implications</i>. N Engl J Med, 2021. 384(19): p. 1866-1868. Boutron, L., et al., <i>The COVID-N4P voccines</i>. Curr Opin Immunol, 2021. 17: p. 111-116. Sisonke. Sisonke study: a pragmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccine candidate among frontline health.core workers in South Africa. Intp://sison/hestudy.samer.ca.zd (accessed 19 September 2021). 2021. NDOH-e. National Department of Health, South Africa. Vaccine updates. 2021 [cited 2022 14 January 2022]. Tri p. 34-45. Wiysonge, C.S., et al., <i>A critical review of measures of childhood vaccine confidence</i>. Curr Opin Immunol, 2021. Tri p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: Summary of existing studies. 2021 [cited 2022] 14 January 2022]; Available from: thys:/sacoronavirus.co.ca/wicein-hesitancy-in.south.africa: south Africa: South Africa: Hum Vaccin Immunother, 2021 and the achievements of vaccina hesitancy in South Africa: South Africa: Hum Vaccin Immunother, 2021. 20(1). Cooper, S., H. van Rooyen, and C.S. Wiysonge, COVID-19 vaccine hesitancy in South Africa: 567	1	Abdool Karim S.S. The South African Response to the Pandemic N Engl I Med 2020 382(24): n e95	546	
 https://www.thinkglobalhealth.org/article/couth-africas-var-covid-19 (accessed 22 December 201), 2020. NDOH-a. National Department of Health. South Africa. Regulations and Relief, 2021 [cited 2022 14 panuary 2022], Available from: <u>https://sacoronavirus.co.2a/guidelines-and-relief</u>. NDOH-b. National Department of Health. South Africa. Covid-19 Daily Updates & Cases. 2021 [cited 2022 14] NDOH-S. National Department of Health. South Africa. Covid-19 Daily Updates & Cases. 2021 [cited 2022 14] And Intern Med. 2020. 194 (19): p. 1866-1868. Boutron, I., et al., The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic. Ann Intern Med. 2020. 173(12): p. 1015-1017. Ndwandwe, D. and C.S. Wiysonge, COVID-19 vaccines. Curr Opin Immunol, 2021. 71: p. 111-116. Sisonke. Sisonke study: a pragmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccine conditate among frontime healthcare workers in South Africa. The provide study. and the partment of Health. South Africa. Tracetine hesitancy in the ar of COVID-19 could lessons from the past help in divining the future? Hum Vaccin Immunother, 2021: p. 1-3. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in the ast of South Africa: 560 South Africa: 501 South Africa: 561 South Africa: 561 South Africa: 562 South Africa: 562 South Africa: 563 South Africa: 564 South Africa: 565 South Africa: 565 South Africa: 566 South Africa: 567 South Africa: 567 South Africa: 567 South Africa: 566 South Africa: 566 South Africa: 566 South Afri				
 NDOH-a. National Department of Health, South Africa. Regulations and Relief. 2021 [cited 2022 14] NDOH-b. National Department of Health, South Africa. Covid-19 Daily Updates & Cases. 2021 [cited 2022 14] Anbdoo Karim, S.S. and T. de Oliveira, New SARS-Corl-2 Variants - Clinical, Public Health, and Vaccine Implications. N Engl J Med, 2021. 384(19): p. 1866-1868. Boutron, L., et al., The COVID-NA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic. Ann Intern Med, 2020. 173(12): p. 1015-1017. Ndwandwe, D. and C.S. Wiysonge, COVID-19 vaccines. Curr Opin Immunol, 2021. 71: p. 111-116. Sisonke. Sisonke study: a progenitic real world phase 36 clinical trial of the single-dose COVID-19 vaccine candidate among frontime healthcare workers in South Africa. http://sisonfaestudy.samrc.ac.zd (accessed 19 September 2021). 2021. NDOH-e. National Department of Health, South Africa. Vaccine updates. 2021 [cited 2022 14] January 2022; Available from: https://sisondexing.sco.ar/acascine.updates. Wiysonge, C.S., et al., Faccine hestiancy in the era of COVID-19 vaccine hestiancy in South Africa. NDOH-e. National Department of Health, South Africa. COVID-19 vaccine hestiancy in South Africa: 560 (2021. 71: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hestiancy in South Africa: 560 (2021. 71: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hestiancy in South Africa: 560 (2021. 71: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hestiancy in South Africa: 560 (2021. 71: p. 34-45. NDOH-G. National Department of Health, South Africa. COVID-19 vaccine hestiancy in South Africa: 560 (2021. 71: p. 34-45. NDOH-G. National Department of Health, South Africa. COVID-19 vaccine hestiancy in South Africa: 560 (2021. 71: p. 34-45. NDOH-G. Natio	4.		547	E10
 Innuary 2022], Available from: https://sacoronavirus.co.za/guidelines-and-relief. NDOH-b- National Department of Health, South Africa. Civid-19 Daily Updates & Cases. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/covid-19-daily-cases/. Abdool Karim, S.S. and T. de Oliveira, New SARS-Col'-2 Variants - Clinical, Public Health, and Vaccine for Intern Med, 2020. 194 [19]; n. 1866-1868. Boutron, I., et al., The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic. Ann Intern Med, 2020. 173(12); p. 1015-1017. Ndwandwe, D. and C.S. Wiysonge, COVID-19 vaccines. Curr Opin Immunol, 2021. 71: p. 11-116. Sisonke Sisonke study: a pragmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccines candidate among frontline healthcare workers in South Africa. <i>Http://Sisonkestudy.samrc.uc.2d/</i> (accessed 19 September 2021). 2021. NDOH-e. National Department of Health, South Africa. Vaccine updates. Shonko, G.K., et al., A critical review of measures of childhood vaccine confidence. Curr Opin Immunol, 2021. 71: p. 34-45. Shonmay, G.K., et al., A critical review of measures of childhood vaccine confidence. Curr Opin Immunol, 2021. 71: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa. 567 Summary of existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021104/12/covid-19-vaccine-hesitancy in-south-africa-summary-of-existing-studies/. Cooper, S., H. van Rooyen, and C.S. Wiysonge, CVID-19 vaccine hesitancy in South Africa. 567 Wilson, S.L. and C. Swiysonge, and G.D. Hussey, Strengthening the expanded programme on maximize uptake of COVID-19 vaccine restrancy. BMJ Glob Health, 2021. 27(8): 573 Machingaidze, S., and C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on	2		E 40	540
 NDOH-b. National Department of Health, South Africa. Covid-19 Daily Updates & Cases. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/covid-19-daily-cases/. Abdool Karim, S.S. and T. de Oliveira, New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. N Engl J Med, 2021. 384(19): p. 1866-1868. Boutron, L, et al., The COVID-MAN Project: Building an Evidence Ecosystem for the COVID-19 Pandemic. Science and date annong frontline healthcare workers in South Africa. Intro/Isionkestudy.camer.ac.zal (accessed 19 September 2021). 2021. NNDOH-e. National Department of Health, South Africa. Vaccine updates. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/Avaccine-updates/. Wiysonge, C.S., et al., Vaccine Instancy in South Africa. CoVID-19 vaccine hesitancy in South Africa: Summary of existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy in-south-africa-summary-of-existing studies. 2021. 20(8): p. 213-933. WHO, World Heath Organization. Data for action: achieving high uptake of COVID-19 vaccine hesitancy in south Africa. Source memory and existing views sho introphytolecovirus (heevements of vaccination programme in Africa. 1, Vaccine hesitancy,	3.		549	0
 Abdool Karim, S.S. and T. de Oliveira, <i>New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications.</i> N. Engl J Med, 2021. 384(19): p. 1866-1868. Boutron, I., et al., <i>The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic.</i> An Intern Med, 2020. 173(12): p. 1015-1017. Ndwandwe, D. and C.S. Wiysonge, <i>COVID-19 vaccines.</i> Curr Opin Immunol, 2021. 71: p. 111-116. Sisonke. Stsonke study: a pragmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccine candidate among frontline healthcare workers in South Africa. <i>http://sisonkestudy.samr.ac.ac.al</i> (accessed 19 September 2021). 2021. NDOH-e. National Department of Health, South Africa. Vaccine updates. 2021 [cited 2022 14 January 2022]: Available from: https://sacoronavirus.co.za/vaccine-updates/. Wiysonge, C.S., et al., <i>A critical review of measures of childhood vaccine confidence.</i> Curr Opin Immunol, 2021. 71: p. 34-43. Shapiro, G.K., et al., <i>A critical review of measures of childhood vaccine confidence.</i> Curr Opin Immunol, 2021. 71: p. 34-43. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines? Expert Rev Vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines? Expert Rev Vaccines, 2021. P.04/WIO, World Health Organization. Data for action: achieving high uptake of VOVID-19 vaccines. Interim guidance. 1 April 2021. https://www.dn.int/publications//ilem/WHO-2019-nCoVuccination-demandplanting.2021.11 (accessed 22 December 2021). 2021. Cooper, S., et al., <i>Faccine hesitancy - a potential threat to the achievements of vaccination regarammes in Africa</i>. Hum Vaccin Immunobler, 2018. 14(10): p. 2355-2357. Machingaidze, S., C.S. Wiysonge, Ouderstanding COVID-19 vaccine hesitancy. Nat Med, 2021. 27(8): p. 1388-1339. Wilson, S.L. and C. Wiysonge, Social m	4		551	550
 Abdool Karim, S.S. and T. de Oliveira, New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. N Engl J Med, 2021. 384(19): p. 1866-1868. Boutron, I., et al., The COVID-19 MAP roject: Building an Evidence Ecosystem for the COVID-19 Pandemic. Ann Intern Med, 2020. 173(12): p. 1015-1017. Ndwandwe, D. and C.S. Wiysonge, COVID-19 vaccines. Curr Opin Immunol, 2021. 71: p. 111-116. Sisonke. Sisonke study: a progmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccine conditate among fronthine healthcare workers in South Africa. Inter://sisonkes.udy.samrc.ac.za/ (accessed 19 September 2021). 2021. NDOH-e. National Department of Health, South Africa. Vaccine updates. Wiysonge, C.S., et al., Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future? Hum Vacci Immunother, 2021: p. 1-3. Shapiro, G.K., et al., A critical review of measures of childhood vaccine confidence. Curr Opin Immunol, 2021. 71: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: Summary of existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing- studies/. Cooper, S., H. van Rooyen, and C.S. Wiysonge, COVID-19 vaccine hesitancy in South Africa: WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccine hesitancy. Cooper, S., et al., Factore hesitancy - a potential threat to the achievements of vaccination-demand planning-2021.11 (accessed 22 December 2021). 2021. Cooper, S., et al., Factore hesitancy - a potential threat to the achievements of vaccination programmes in Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S., C.S. Wiysonge, Odd D. Hussey, Strengthening the expanded program	4.		551	550
 Implications. N Engl J Mcd, 2021, 384(19): p. 1866-1868. Boutron, I., et al., <i>The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic.</i> Nodwandwe, D. and C.S. Wiysonge, <i>COVID-19 vaccines</i>. Curr Opin Immunol, 2021. 71: p. 111-116. Sisonke Stavke study: a pragmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccines. Sisonke Stavke study: a pragmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccines. Sisonke Stavke study: a pragmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccine. NDOH-e. National Department of Health, South Africa. Vaccine updates. Wiysonge, C.S., et al., <i>Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future</i>? Hum Vaccin Immunother, 2021: p. 1-3. Shapiro, G.K., et al., <i>A critical review of measures of childhood vaccine confidence</i>. Curr Opin Immunol, 2021, 71: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: 567 Summary of existing studies. 2021 [cited 2022] 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing-studies. Cooper, S., H. van Rooyen, and C.S. Wiysonge, <i>COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines besting high uptake of COVID-19 vaccines. Interim guidance. I April 2021. https://www.who.int/publications/i/tem/WHO-2019-nCoV-vaccination-demand-planning-2021.1 (accessed 22 December 2021). 2021.</i> Cooper, S., et al., Caccine hesitancy: a potential threat to the achievements of vaccination programmes in <i>Africa</i>. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S. and C.S. Wiysonge, Understanding COVID-19 vaccine hesitancy. Nat Med, 2021. 27(8). Wilson, S.L. and C.	5		552	552
 Boutron, I., et al., <i>The COVID-19MA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic.</i> 555 Advandwe, D. and C.S. Wiysonge, <i>COVID-19 vaccines.</i> Curr Opin Immunol, 2021. 71: p. 111-116. 557 Ndwandwe, D. and C.S. Wiysonge, <i>COVID-19 vaccines.</i> Curr Opin Immunol, 2021. 71: p. 111-116. 557 Sisonke, <i>Sisonke study: a pragmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccine candidate among from the halthcare workers in South Africa. http://sisonkestudy.samrc.ac.za/ (accessed 19 September 2021). 2021.</i> NDOH-e. <i>National Department of Health, South Africa. Vaccine updates.</i> 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/vaccine-updates/. Wiysonge, C.S., et al., <i>I acritical review of measures of childhood vaccine confidence.</i> Curr Opin Immunol, 2021. 71: p. 34-45. NDOH-d. <i>National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa:</i> 567 NDOH-d. <i>National Department of Health, South Africa.</i> COVID-19 vaccine hesitancy in South Africa: 567 Cooper, S., H. van Rooyen, and C.S. Wiysonge, <i>COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines</i>? Suppt Rev Vaccines, 2021. 20(2); p. 921-933. WHO, <i>World Health Organization. Data for action: achieving high uptake of COVID-19 vaccinand-mamad- planning_2021.1 (accessed 22 December 2021). 2021.</i> Cooper, S., et al., <i>Vaccine hesitancy a potential threat to the achievements of vaccination programme in Africa: looking beyond 2015.</i> PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., <i>Faccios that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative vidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. C4013265.</i> Wiysong, S.L. ad C. Wiysonge, Social media and vaccine hesitancy. Bud Glob Health, 2020. 5(10).	5.		553	EE 4
 Ann Intern Med, 2020. 173(12): p. 1015-1017. Ndwandwe, D. and C.S. Wiysonge, <i>COVID-19 vaccines</i>. Curr Opin Immunol, 2021. 71: p. 111-116. Sisonke. Sisonke study: a pragmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccine condidate among frontline healthcare workers in South Africa. http://sisonkestudy.samrc.ac.zd/ (accessed 19 September 2021), 2021. NDOH-c. National Department of Health, South Africa. Vaccine updates. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/vaccine-updates/ Wiysonge, C.S., et al., A critical review of measures of childhood vaccine confidence. Curr Opin Immunol, 2021. 71: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: 566 NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: 567 NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: 568 NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: 568 NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: 568 NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: 568 NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: 568 Muchingaidze, S. and C.S. Wiysonge, COVID-19 vaccine hesitancy in South Africa: 570 Cooper, S., et al., Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S. and C.S. Wiysonge, Understanding COVID-19 vaccine hesitancy. Nat Med, 2021. 27(8): 570 Machingaidze, S. and C.S. Wiysonge, Oil D. Hussey, Strengthening the expanded programme on immunation in Af	6		FFF	554
 Ndwandwe, D. and C.S. Wiysonge, COVID-19 vaccines. Curr Opin Immunol, 2021. 71: p. 111-116. Sisonke. Sisonke study: a pragmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccine 19 September 2021). 2021. NDOH-e. National Department of Health, South Africa. Vaccine updates. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/vaccine-updates/. Wiysonge, C.S., et al., Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future? Hum Vaccin Immunother, 2021: p. 1-3. Shapiro, G.K., et al., A critical review of measures of childhood vaccine confidence. Curr Opin Immunol, 2021. 71: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: Summary of existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines? Expert Rev Vaccines, 2021. 20(8): p. 921-933. WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. https://www.who.int/publications/ittem/WHO-2019-nCoV-vaccination-demand-planning-2021.1 (accessed 22 December 2021). 2021. Cooper, S., et al., Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa: Noking beyond 2015. PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. 2355-2357. Machingaidze, S., C.S. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). Wiysong, C.S., Yaccine hesitancy in South Africa. Wave meed to adapt validated measures. https://www.ondation-merieux.org/wp	0.		555	FFC
 Sisonke Sisonke study: a pragmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccine for and date among frontline healthcare workers in South Africa. http://sisonkestudy.samrc.ac.ad/ (accessed 19 September 2021). 2021. NDOH-e. National Department of Health, South Africa. Vaccine updates. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/vaccine-updates/. Wiysonge, C.S., et al., Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future? Hum Vaccin Immunother, 2021: p. 1-3. Shapiro, G.K., et al., A critical review of measures of childhood vaccine confidence. Curr Opin Immunol, 2021: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: 567 NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: 567 NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines? Expert Rev Vaccines, 2021. 20(8): p. 921-933. WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. https://www.who.in/publications/litem/WHO-2019-nCOV-vaccination-demand-planning-2021.1 (accessed 22 December 2021). 2021. Cooper, S., et al., Vaccine hesitancy a potential threat to the achievements of vaccination programmes in Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S., and C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on immunization in Africa: onking and and vaccine hesitancy. Nat Med, 2021. 27(8): p. 1338-1339. Wiysong, C. S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p.	7		557	556
 candidate among fromtline healthcare workers in South Africa. http://sisonkestudy.samrc.ac.za/ (accessed 19 September 2021). 2021. NDOH-c. National Department of Health, South Africa. Vaccine updates. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/vaccine-updates/. Wiysonge, C.S., et al., Vaccine hesitancy in the era of COVID-19 could lessons from the past help in dvining the future? Hum Vaccin Immunother, 2021: p. 1-3. Shapiro, G.K., et al., A critical review of measures of childhood vaccine confidence. Curr Opin Immunol, 2021. 71: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: Summary of existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing-studies/. Cooper, S., H. van Rooyen, and C.S. Wiysonge, COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines? Expert Rev Vaccines, 2021. 20(8): p. 921-933. WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. https://www.hoi.int/publications/iitem/WHO-2019-nCoV-vaccination-demand-planning-2021.1 (accessed 22 December 2021). 2013. Machingaidze, S., et al., Vaccine hesitancy - a potential threat to the achievements of vaccination programme on immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S., et al., Vaccine heyond 2015. PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. 26013265. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. Mtwissing. Misous formation: an facebook post				
 19 September 2021), 2021. NDOH-c. National Department of Health, South Africa. Vaccine updates, 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/vaccine-updates/. Wiysonge, C.S., et al., <i>Yaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future</i>? Hum Vaccin Immunother, 2021; p. 1-3. Shapiro, G.K., et al., <i>A critical review of measures of childhood vaccine confidence</i>. Curr Opin Immunol, 2021. T1: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: Summary of existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing-studies/. Cooper, S., H. van Rooyen, and C.S. Wiysonge, <i>COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines?</i> Expert Rev Vaccines, 2021. 20(8): p. 291-933. WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. https://www.who.int/publications//item/WHO-2019-nCoV-vaccination-demandplanning-2021.1 (accessed 22 December 2021). 201. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. G013265. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. Hysisonge, p. 41, Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa: Research and policy agenda. S Afr Med J. 2018. 19(1): p. 13-15. Oduwole, E.O., et al., Point-of-care vaccination' preceptions of vaccine hesitancy drivers: A qualitative study from	0.		556	550
 NDOÌ-E. National Department of Health, South Africa. Vaccine updates. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/vaccine-updates/. Wiysonge, C.S., et al., <i>Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future?</i> Hum Vaccin Immunother, 2021; p. 1-3. Shapiro, G.K., et al., <i>A critical review of measures of childhood vaccine confidence.</i> Curr Opin Immunol, 2021. T1: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: Summary of existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing-studies/. Cooper, S., H. van Rooyen, and C.S. Wiysonge, <i>COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines</i>? Expert Rev Vaccines, 2021. 20(8): p. 921-933. WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021 https://www.who.int/publications/iftem/WHO-2019-ncOV-vaccination-demandplanning-20211. (accessed 22 December 2021). 2021. Cooper, S., et al., <i>Vaccine hesitancy - a potential threat to the achievements of vaccination programme on immunization in Africa: looking beyond 2015</i>. PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., <i>Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccine hesitancy in South Africa: wave in South Africa: wave in South Africa. Vaccine hesitancy in South Africa: wave in hesitancy in South Africa: wave in the steam of the alth provide insights into determinants of vaccine hesitancy in South Africa: Research and policy agenda. S Afr Med 1, 2018. 109(1): p. 13-15.</i> Oduwole, E.O., et al., <i>Porint-of-care vaccination' preceptions of vaccine hesitancy drivers: A qualitative study from</i>				
 2022]; Available from: https://sacoronavirus.co.za/vaccine-updates/. Wiysonge, C.S., et al., <i>Paccine hesitancy in the era of COPD-19: could lessons from the past help in dvining the future?</i> Hum Vaccin Immunother, 2021: p. 1-3. Shapiro, G.K., et al., <i>A critical review of measures of childhood vaccine confidence</i>. Curr Opin Immunol, 2021. 71: p. 34-45. NDOH-d. <i>National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: Summary of existing studies</i>. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing-studies/. Cooper, S., H. van Rooyen, and C.S. Wiysonge, <i>COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines?</i> Expert Rev Vaccines, 2021. 20(8): p. 921-933. WHO, <i>World Health Organization. Data for action: achieving high uptake of COVID-19 vaccination-demand-planning-2021.1 (accessed 22 December 2021)</i>, 2021. Cooper, S., et al., <i>Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa.</i> Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S. and C.S. Wiysonge, and G.D. Hussey, <i>Strengthening the expanded programme on immunization in Africa: looking beyond 2015.</i> PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., <i>Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis.</i> Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wilson, S.L. and C. Wiysonge, <i>Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa. Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa. Vaccine, e</i>	9		561	500
 Wiysonge, C.S., et al., <i>Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future?</i> Hum Vaccin Immunother, 2021: p. 1-3. Shapiro, G.K., et al., <i>A critical review of measures of childhood vaccine confidence</i>. Curr Opin Immunol, 2021. 71: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: Summary of existing studies. 2021 [cited 2022 14 January 2022]: Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing-studies. Cooper, S., H. van Rooyen, and C.S. Wiysonge, <i>COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines?</i> Expert Rev Vaccines, 2021. 20(8): p. 921-933. WHO, <i>World Health Organization. Data for action: achieving high uptake of COVID-19 vaccine hesitancy - a potential threat to the achievements of vaccination-demand-planning-2021.1 (accessed 22 December 2021). 2021.</i> Cooper, S., et al., <i>Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa:</i> Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, <i>Strengthening the expanded programme on infumination in Africa: looking beyond 2015.</i> PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., <i>Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis.</i> Cochrane Database Syst Rev, 2021. 10(10): p. C4013265. Wilyon, S.L. and C. Wiysonge, <i>Social media and vaccine hesitancy.</i> BMJ Glob Health, 2020. 5(10). Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. <i>Mythys./www.fondation-mericus.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysong egdf</i> (accessed 22 December 2021). 2018. Wiysonge, C.S., tal., <i>Aprofil</i>).		501	562
 divining the future? Hum Vaccin Immunother, 2021: p. 1-3. Shapiro, G.K., et al., <i>A critical review of measures of childhood vaccine confidence</i>. Curr Opin Immunol, 2021. Tri: p. 34-45. NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: Summary of existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing-studies/. Cooper, S., H. van Rooyen, and C.S. Wiysonge, COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines? Expert Rev Vaccines, 2021. 20(8); p. 921-933. WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccinas. Interim guidance. 1 April 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccination-demand-planning-2021.1 (accessed 22 December 2021). 201. Cooper, S., et al., Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. Ca013265. Wilson, S.L. and C. Wiysonge, Social media and MPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. Oduwole, E.O., et al., Point-of-care vaccination' perceptions of vaccine hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1)	10		563	502
 Shapiro, G.K., et al., <i>A critical review of measures of childhood vaccine confidence</i>. Curr Opin Immunol, 2021. 71: p. 34-45. NDOH-d. <i>National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: Soummary of existing studies.</i> 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing-studies/. Cooper, S., H. van Rooyen, and C.S. Wiysonge, <i>COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines?</i> Expert Rev Vaccines, 2021. 20(8): p. 921-933. WHO, <i>World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. https://www.who.int/publications//item/WHO-2019-nCOV-vaccination-demandplanning-2021.1 (accessed 22 December 2021). 201.</i> Cooper, S., et al., <i>Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa.</i> Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, <i>Strengthening the expanded programme on immunization in Africa: looking beyond 2015.</i> PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., <i>Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis.</i> Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wiysonge, C.S., <i>Vaccial media and PV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15.</i> Ngeobo, N.J., et al., <i>A profile of anti-vaccination in Coreptance and hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2011-2013. S Afr</i> 	10.		000	564
 2021. 71: p. 34-45. 2000 NDH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: Summary of existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing-studies/. 3. Cooper, S., H. van Rooyen, and C.S. Wiysonge, <i>COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines</i>? Expert Rev Vaccines, 2021. 20(8): p. 921-933. 14. WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. https://www.who.int/publications//titem/WHO-2019-nCoV-vaccination-demand-planning-2021/. (accessed 22 December 2021). 201. 55. Cooper, S., et al., Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. 16. Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med, 2013. 10(3): p. e1001405. 79. Machingaidze, S., and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). 20. Wiyson, S.L. and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). 21. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge and flamedia and HPV vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. 22. Ngcobo, N.J., et al., Point-of-care vaccinatiors' perceptions of vaccine hesitancy wirers: A qualitative study from the cape metropolitan district, South Africa: Naccine, 2021. 30(3): p. 5506-5512. 24. Burnett, R.J., et al., Point-of-care vaccination' preceptions of vaccine hesitancy wirers: A qual	11		565	504
 NDOH-d. National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: 567 Summary of existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing-studies/. Cooper, S., H. van Rooyen, and C.S. Wiysonge, COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines? Expert Rev Vaccines, 2021. 20(8): p. 921-933. WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. https://www.who.int/publications//item/WHO-2019-nCoV-vaccination-demand-planning-2021.1 (accessed 22 December 2021). 2021. Cooper, S., et al., Vaccine hesitancy - a potential threat to the achievements of vaccination programme in Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge.pdf (accessed 22 December 2021). 2018. Ngeobo, N.J., et al., Point-of-care vaccinatiors' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2011-2013. S Afr Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South Africa intervet: 2011-2013. S Afr 	11.		505	566
 Summary of existing studies. 2021 [cited 2022 14 January 2022]; Available from: https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing-studies. Cooper, S., H. van Rooyen, and C.S. Wiysonge, <i>COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines</i>? Expert Rev Vaccines, 2021. 20(8): p. 921-933. WHO, <i>World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. https://www.who.int/publications/i/tem/WHO-2019-nCoV-vaccination-demandplanming-2021.1 (accessed 22 December 2021). 2021.</i> Cooper, S., et al., <i>Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa.</i> Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S. and C.S. Wiysonge, and G.D. Hussey, <i>Strengthening the expanded programme on immunization in Africa: looking beyond 2015.</i> PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., <i>Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis.</i> Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wilson, S.L. and C. Wiysonge, <i>Social media and vaccine hesitancy.</i> BMJ Glob Health, 2020. 5(10). Wiysonge, C.S., <i>Vaccine hesitancy in South Africa: why we need to adapt validated measures. Africa.</i> Vaccine, 2019. 37(43): p. 6317-6323. Wiysonge, C.S., <i>Vaccine hesitancy in South Africa: why we need to adapt validated measures. Mysonge. pdf (accessed 22 December 2021).</i> 2018. Ngeobo, N.J., et al., <i>Point-of-care vaccination acceptance and hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa.</i> Vaccine, 2021. 39(39): p. 5506-5512. Burnett, R.J., et al., <i>Point-of antivaccination lobbying on the South Africa intermet, 2011-2013</i>. S Afr 	12		567	000
https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing- studies/. 569 13. Cooper, S., H. van Rooyen, and C.S. Wiysonge, COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines? Expert Rev Vaccines, 2021. 20(8): p. 921-933. 571 14. WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. https://www.who.int/publications/l/item/WHO-2019-nCoV-vaccination-demand- planning-2021.1 (accessed 22 December 2021). 2021. 573 15. Cooper, S., et al., Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. 576 16. Machingaidze, S. and C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med, 2013. 10(3): p. e1001405. 580 18. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. 582 19. Wilson, S.L. and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). 583 20. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles- wiysonge, pdf (accessed 22 December 2021). 2018. 591 21. Ngcobo, N.J., et al., Point-of-care vaccinatiors' perceptions of vaccine hesitancy drivers: A qualitative study			00.	568
 studies/. studies/. Cooper, S., H. van Rooyen, and C.S. Wiysonge, <i>COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines</i>? Expert Rev Vaccines, 2021. 20(8): p. 921-933. WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. https://www.who.int/publications//item/WHO-2019-nCoV-vaccination-demand-planning-2021.1 (accessed 22 December 2021). 2021. Cooper, S., et al., Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S. and C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wiyson, S.L. and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge.pdf (accessed 22 December 2021). 2018. Ngcobo, N.J., et al., Point-of-care vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Aft Med J, 2018. 109(1): p. 13-15. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South Africa internet, 2011-2013. S Aft 				
 Cooper, S., H. van Rooyen, and C.S. Wiysonge, <i>COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines?</i> Expert Rev Vaccines, 2021. 20(8): p. 921-933. WHO, <i>World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. https://www.who.int/publications/i/item/WHO-2019-nCOV-vaccination-demand-planning-2021.1 (accessed 22 December 2021). 2021.</i> Cooper, S., et al., <i>Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa.</i> Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S. and C.S. Wiysonge, <i>Understanding COVID-19 vaccine hesitancy.</i> Nat Med, 2021. 27(8): p. 1338-1339. Machingaidze, S., c.S. Wiysonge, and G.D. Hussey, <i>Strengthening the expanded programme on immunization in Africa: looking beyond 2015.</i> PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., <i>Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis.</i> Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wilson, S.L. and C. Wiysonge, <i>Social media and vaccine hesitancy.</i> BMJ Glob Health, 2020. 5(10). Wiysonge, C.S., <i>Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge. pdf (accessed 22 December 2021).</i> 2018. Wiysonge, C.S., <i>Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge. pdf (accessed 22 December 2021).</i> 2018. Ngcobo, N.J., et al., <i>Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative signs sudy from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512.</i> Burn				
 maximize uptake of COVID-19 vaccines? Expert Rev Vaccines, 2021. 20(8): p. 921-933. WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccination-demand-planning-2021.1 (accessed 22 December 2021). 2021. Cooper, S., et al., Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S., and C.S. Wiysonge, Understanding COVID-19 vaccine hesitancy. Nat Med, 2021. 27(8): p. 1338-1339. Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wilson, S.L. and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge. gard.a S Aft Med J, 2018. 109(1): p. 13-15. Oduwole, E.O., et al., Point-of-care vaccination acceptance and hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South Africa internet, 2011-2013. S Aft 	13.		571	
 WHO, World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccination-demand-planning-2021.1 (accessed 22 December 2021). 2021. Cooper, S., et al., Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S. and C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wilson, S.L. and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge.pdf (accessed 22 December 2021). 2018. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. Oduwole, E.O., et al., Point-of-care vaccination lobbying on the South Africa internet, 2011-2013. S Afr 				572
 planning-2021.1 (accessed 22 December 2021). 2021. 15. Cooper, S., et al., Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. 16. Machingaidze, S. and C.S. Wiysonge, Understanding COVID-19 vaccine hesitancy. Nat Med, 2021. 27(8): 578 p. 1338-1339. 17. Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med, 2013. 10(3): p. e1001405. 18. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. 19. Wilson, S.L. and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). 10. Wiyeh, A.B., et al., Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa. Vaccine, 2019. 37(43): p. 6317-6323. 11. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge.pdf (accessed 22 December 2021). 2018. 20. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. 23. Oduwole, E.O., et al., Point-of-care vaccinatior' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. 24. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South African internet, 2011-2013. S Afr 	14.		573	
 Cooper, S., et al., <i>Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa.</i> Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S. and C.S. Wiysonge, <i>Understanding COVID-19 vaccine hesitancy.</i> Nat Med, 2021. 27(8): p. 1338-1339. Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, <i>Strengthening the expanded programme on immunization in Africa: looking beyond 2015.</i> PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., <i>Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis.</i> Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wilson, S.L. and C. Wiysonge, <i>Social media and vaccine hesitancy.</i> BMJ Glob Health, 2020. 5(10). Wiysonge, C.S., <i>Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge.pdf (accessed 22 December 2021).</i> 2018. Ngcobo, N.J., et al., <i>Human papillomavirus vaccinations acceptance and hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa.</i> Vaccine, 2021. 39(39): p. 5506-5512. Burnett, R.J., et al., <i>A profile of anti-vaccination lobbying on the South African internet, 2011-2013.</i> S Afr 		guidance. 1 April 2021. <u>https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccination-demand-</u>		574
 Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357. Machingaidze, S. and C.S. Wiysonge, Understanding COVID-19 vaccine hesitancy. Nat Med, 2021. 27(8): p. 1338-1339. Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wilson, S.L. and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). Wiyeh, A.B., et al., Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa. Vaccine, 2019. 37(43): p. 6317-6323. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge.pdf (accessed 22 December 2021). 2018. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. Oduwole, E.O., et al., Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South African internet, 2011-2013. S Afr 		<u>planning-2021.1</u> (accessed 22 December 2021). 2021.		575
 Machingaidze, S. and C.S. Wiysonge, Understanding COVID-19 vaccine hesitancy. Nat Med, 2021. 27(8): 578 p. 1338-1339. Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wilson, S.L. and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). Wiyeh, A.B., et al., Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa. Vaccine, 2019. 37(43): p. 6317-6323. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge.pdf (accessed 22 December 2021). 2018. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. Oduwole, E.O., et al., Point-of-care vaccinations' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South Africa internet, 2011-2013. S Afr 	15.	Cooper, S., et al., Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in	576	
 p. 1338-1339. 17. Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med, 2013. 10(3): p. e1001405. 18. Cooper, S., et al., Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. 19. Wilson, S.L. and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). 20. Wiyeh, A.B., et al., Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa. Vaccine, 2019. 37(43): p. 6317-6323. 21. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge.pdf (accessed 22 December 2021). 2018. 22. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Aft Med J, 2018. 109(1): p. 13-15. 23. Oduwole, E.O., et al., Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. 24. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South Africa internet, 2011-2013. S Afr 		Africa. Hum Vaccin Immunother, 2018. 14(10): p. 2355-2357.		577
 Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, <i>Strengthening the expanded programme on immunization in Africa: looking beyond 2015.</i> PLoS Med, 2013. 10(3): p. e1001405. Cooper, S., et al., <i>Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis.</i> Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wilson, S.L. and C. Wiysonge, <i>Social media and vaccine hesitancy.</i> BMJ Glob Health, 2020. 5(10). Wiyeh, A.B., et al., <i>Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa.</i> Vaccine, 2019. 37(43): p. 6317-6323. Wiysonge, C.S., <i>Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge.pdf (accessed 22 December 2021). 2018.</i> Ngcobo, N.J., et al., <i>Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda.</i> S Afr Med J, 2018. 109(1): p. 13-15. Oduwole, E.O., et al., <i>Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa.</i> Vaccine, 2021. 39(39): p. 5506-5512. Burnett, R.J., et al., <i>A profile of anti-vaccination lobbying on the South African internet, 2011-2013.</i> S Afri 	16.		578	
 <i>immunization in Africa: looking beyond 2015.</i> PLoS Med, 2013. 10(3): p. e1001405. 18. Cooper, S., et al., <i>Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis.</i> Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. 19. Wilson, S.L. and C. Wiysonge, <i>Social media and vaccine hesitancy.</i> BMJ Glob Health, 2020. 5(10). 20. Wiyeh, A.B., et al., <i>Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa.</i> Vaccine, 2019. 37(43): p. 6317-6323. 21. Wiysonge, C.S., <i>Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wivsonge.pdf (accessed 22 December 2021). 2018.</i> 22. Ngcobo, N.J., et al., <i>Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda.</i> S Afr Med J, 2018. 109(1): p. 13-15. 23. Oduwole, E.O., et al., <i>Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa.</i> Vaccine, 2021. 39(39): p. 5506-5512. 24. Burnett, R.J., et al., <i>A profile of anti-vaccination lobbying on the South African internet, 2011-2013.</i> S Afri 				579
 Cooper, S., et al., <i>Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis.</i> Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. Wilson, S.L. and C. Wiysonge, <i>Social media and vaccine hesitancy.</i> BMJ Glob Health, 2020. 5(10). Wiyeh, A.B., et al., <i>Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa.</i> Vaccine, 2019. 37(43): p. 6317-6323. Wiysonge, C.S., <i>Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge.pdf (accessed 22 December 2021). 2018.</i> Ngcobo, N.J., et al., <i>Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda.</i> S Afr Med J, 2018. 109(1): p. 13-15. Oduwole, E.O., et al., <i>Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa.</i> Vaccine, 2021. 39(39): p. 5506-5512. Burnett, R.J., et al., <i>A profile of anti-vaccination lobbying on the South African internet, 2011-2013.</i> S Afr 	17.		580	
 routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev, 2021. 10(10): p. Cd013265. 19. Wilson, S.L. and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). 20. Wiyeh, A.B., et al., Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa. Vaccine, 2019. 37(43): p. 6317-6323. 21. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge.pdf (accessed 22 December 2021). 2018. 22. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. 23. Oduwole, E.O., et al., Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. 24. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South African internet, 2011-2013. S Afr 				581
 p. Cd013265. 19. Wilson, S.L. and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). 20. Wiyeh, A.B., et al., Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa. Vaccine, 2019. 37(43): p. 6317-6323. 21. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles- wiysonge.pdf (accessed 22 December 2021). 2018. 22. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. 23. Oduwole, E.O., et al., Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. 24. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South African internet, 2011-2013. S Afr 	18.		582	
 Wilson, S.L. and C. Wiysonge, Social media and vaccine hesitancy. BMJ Glob Health, 2020. 5(10). Wiyeh, A.B., et al., Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa. Vaccine, 2019. 37(43): p. 6317-6323. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. <u>https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles- wiysonge.pdf</u> (accessed 22 December 2021). 2018. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. Oduwole, E.O., et al., Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South African internet, 2011-2013. S Afr 				
 Wiyeh, A.B., et al., Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa. Vaccine, 2019. 37(43): p. 6317-6323. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. <u>https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles- wiysonge.pdf</u> (accessed 22 December 2021). 2018. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. Oduwole, E.O., et al., Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South African internet, 2011-2013. S Afr 	10			584
by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa. Vaccine, 2019. 37 (43): p. 6317-6323.58721. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles- wiysonge.pdf (accessed 22 December 2021). 2018.58922. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109 (1): p. 13-15.59123. Oduwole, E.O., et al., Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39 (39): p. 5506-5512.59224. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South African internet, 2011-2013. S Afr594				
 Africa. Vaccine, 2019. 37(43): p. 6317-6323. 21. Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles- wiysonge.pdf (accessed 22 December 2021). 2018. 22. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. 23. Oduwole, E.O., et al., Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. 24. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South African internet, 2011-2013. S Afr 	20.		586	
 Wiysonge, C.S., Vaccine hesitancy in South Africa: why we need to adapt validated measures. 589 <u>https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-</u>590 <u>wiysonge.pdf</u> (accessed 22 December 2021). 2018. 591 Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. 593 Oduwole, E.O., et al., Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. 595 Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South African internet, 2011-2013. S Afr 				
https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles- wiysonge.pdf (accessed 22 December 2021). 2018. 590 22. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. 592 23. Oduwole, E.O., et al., Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. 594 24. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South African internet, 2011-2013. S Afr 596	0.1			588
 wiysonge.pdf (accessed 22 December 2021). 2018. 22. Ngcobo, N.J., et al., Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. 23. Oduwole, E.O., et al., Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. 24. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South African internet, 2011-2013. S Afr 	21.		589	
 Ngcobo, N.J., et al., <i>Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda.</i> S Afr Med J, 2018. 109(1): p. 13-15. Oduwole, E.O., et al., <i>Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa.</i> Vaccine, 2021. 39(39): p. 5506-5512. Burnett, R.J., et al., <i>A profile of anti-vaccination lobbying on the South African internet, 2011-2013.</i> S Afr 				
 and policy agenda. S Afr Med J, 2018. 109(1): p. 13-15. 23. Oduwole, E.O., et al., Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa. Vaccine, 2021. 39(39): p. 5506-5512. 24. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South African internet, 2011-2013. S Afr 596 	าา		EOD	391
 23. Oduwole, E.O., et al., <i>Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa.</i> Vaccine, 2021. 39(39): p. 5506-5512. 24. Burnett, R.J., et al., <i>A profile of anti-vaccination lobbying on the South African internet, 2011-2013.</i> S Afr 596 	44.		392	502
<i>study from the cape metropolitan district, South Africa.</i> Vaccine, 2021. 39 (39): p. 5506-5512. 595 24. Burnett, R.J., et al., <i>A profile of anti-vaccination lobbying on the South African internet, 2011-2013.</i> S Afr 596	23		59/	093
24. Burnett, R.J., et al., A profile of anti-vaccination lobbying on the South African internet, 2011-2013. S Afr 596	<i>2</i> 9.		574	595
	24		596	570
	21.		570	597

25.	Milondzo, T., et al., Misinformation Drives Low Human Papillomavirus Vaccination Coverage in South	598	
	African Girls Attending Private Schools. Front Public Health, 2021. 9: p. 598625.		599
26.	Wiysonge, C.S., et al., Advances in childhood immunisation in South Africa: where to now? Programme	600	
	managers' views and evidence from systematic reviews. BMC Public Health, 2012. 12: p. 578.		601
27.	Larson, H.J., et al., Understanding vaccine hesitancy around vaccines and vaccination from a global	602	
	perspective: a systematic review of published literature, 2007-2012. Vaccine, 2014. 32(19): p. 2150-9.		603
28.	WHO, Data for action: Achieving high uptake of COVID-19 vaccines – A guidebook for immunization	604	
	programmes and implementing partners. Draft version of 26 November 2020 (Corsspondence to Ms Lisa		605
	Menning: menningl@who.int) 2020.		606
29.	Bronfenbrenner, U., Ecological models of human development, in International Encyclopedia of Education.	607	
	1994, Elsevier: Oxford. p. 1643-1647.		608
30.	Swann, C., Action Research and the Practice of Design. Design Issues, 2002. 18(1): p. 49-61.	609	
31.	Grimmer, K., et al., A South African experience in applying the Adopt-Contextualise-Adapt framework to	610	
	stroke rehabilitation clinical practice guidelines. Health Res Policy Syst, 2019. 17(1): p. 56.		611
32.	Yin, R.K., Case study research: design and methods. 5th ed. 2014, Thousand Oaks, CA: Sage Publications,	612	
	Inc.		613
33.	NDOH-e. National Department of Health, South Africa. Update on Covid-19 (29th January 2021). 2021	614	
	[cited 2021 29 January 2021]; Available from: https://sacoronavirus.co.za/2021/01/29/update-on-covid-		615
	19-29th-january-2021/.		616
34.	Faul, F., et al., Power 3: A flexible statistical power analysis program for the social, behavioral, and	617	
	biomedical sciences. Behavior Research Methods, 2007. 39: p. 175-191.		618
35.	Groenewald, C., et al., A qualitative report on learners' experiences and perceptions of the 'It starts today'	619	
	intervention. AwARE.org 2018.		620
36.	Groenewald, C. and Z. Essack, Bring a picture, song or poem: the expression session approach. Paper	621	
	presented at the 32nd International Congress of Psychology (ICP), Prague, Czech Republic (virtual		622
	attendance), 18-23 July 2021, in 32nd International Congress of Psychology (ICP). 2021: Prague, Czech		623
	Republic.		624
37.	Peabody, C.G., Using Photovoice as a Tool to Engage Social Work Students in Social Justice. Journal of	625	
	Teaching in Social Work, 2013. 33 (3): p. 251-265.		626
38.	Braun, V. and V. Clarke, Using thematic analysis in psychology. Qualitative Research in Psychology, 2006.	627	
	3 (2): p. 77-101.		628
39.	Bazeley, P. and K. Jackson, Qualitative Data Analysis with NVivo. 2nd ed. 2013, London, UK: SAGE	629	
	Publications Ltd.		630
40.	Charmaz, K., Constructing Grounded Theory: A Practical Guide through Qualitative Analysis. 2nd ed. 2006,	631	
	London, UK: SAGE Publications Ltd.		632
41.	Koen, J., et al., Payment of trial participants can be ethically sound: moving past a flat rate. S Afr Med J,	633	
	2008. 98 (12): p. 926-9.		634
42.	NHREC, Payment of trial participants in South Africa: Ethical considerations for Research Ethics	635	
	Committees. National Health Research Ethics Council, South Africa. 2012.		636
43.		637	
	Africa. Expert Rev Vaccines, 2022: p. 1-11.		638
		639	




Figure 1




Figure 2